Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...

Despite a 4% revenue drop, Myriad Genetics Inc (MYGN) focuses on operational efficiencies and strategic product launches to ...

Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management ...

Myriad Genetics (($MYGN)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Myriad Genetics ...

With early career and workforce model changes, successful companies need a new approach to training the pipeline.

Despite decades of efforts to improve school attendance and truancy, a KXAN investigation found Texas doesn’t track student ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million.

Among a myriad of problems affecting women in sport, the vast majority of football boots are designed with men’s feet in mind ...

Netflix’s Death by Lightning retells James Garfield’s assassination. See the eight U.S. presidents who never finished their ...

MaryBeth Lewis was shopping for groceries at her local Walmart in suburban Buffalo when she got the word: Her surrogate had just been induced. She rushed home and packed a bag for her new twins — a ...

From 1875 to today, Jacksonville Memorial Hospital has grown with its community, earning Magnet status and expanding access ...

Annual growth of 3% to continue as company diversifies into new products/services, according to UK managing director Lakshmi ...